文献速递流行病学与生物统计真实世界研究与卫生经济

使用因果建模的非随机研究可能给出与随机对照试验不同的答案:一项元流行病学研究

Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study.
PubMed 文献 · J Clin Epidemiol · 2019-11-05

该元流行病学研究比较了使用边际结构模型(MSM)的非随机研究与随机对照试验(RCT)的疗效估计一致性。主要分析纳入19项MSM研究(1,039,570例患者)和141项RCT(120,669例患者),发现8个临床问题(42%)中MSM研究效应方向与RCT相反,9个临床问题(47%)中MSM研究的95%CI未包含RCT估计值。总体未发现获益或危害的系统性分歧,但置信区间较宽(汇总比值比sROR 1.04;95%CI 0.88至1.23)。

要点

  • 42%的临床问题中MSM研究效应方向与RCT相反,47%的95%CI未包含RCT估计值。
  • 两种设计效应估计中位绝对偏差OR为1.58(IQR 1.37至2.16)。
  • 总体无系统性分歧(sROR 1.04;95%CI 0.88至1.23),但置信区间宽。

核心结论

  • 使用MSM因果建模的非随机研究可能给出与RCT不同的答案,将非随机「真实世界」证据用于医疗决策时仍需谨慎。

研究设计与样本

  • 元流行病学研究,纳入提供任何治疗任何医疗结局效应估计的MSM研究,并系统检索同一临床问题的RCT,比较效应方向、效应量和置信区间。

主要发现

  • 主要分析纳入19项MSM研究(1,039,570例患者)和141项RCT(120,669例患者)。
  • 8个临床问题(42%)中MSM研究效应方向与RCT相反,9个临床问题(47%)中MSM研究95%CI未包含RCT估计值。
  • 两种设计效应估计中位绝对偏差OR为1.58(IQR 1.37至2.16)。
  • 总体无获益或危害的系统性分歧,但置信区间宽(sROR 1.04;95%CI 0.88至1.23)。
  • 聚焦医疗决策的MSM研究亚组倾向于高估实验性治疗获益(sROR 1.44;95%CI 0.99至2.09)。

临床怎么用

  • 将非随机「真实世界」证据用于医疗决策时仍需谨慎。

局限性

  • 总体分析置信区间宽(sROR 1.04;95%CI 0.88至1.23)。
  • 聚焦医疗决策的MSM研究亚组置信区间宽(sROR 1.44;95%CI 0.99至2.09)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate how estimated treatment effects agree between nonrandomized studies using causal modeling with marginal structural models (MSM-studies) and randomized trials (RCTs). STUDY DESIGN: Meta-epidemiological study. SETTING: MSM-studies providing effect estimates on any healthcare outcome of any treatment were eligible. We systematically sought RCTs on the same clinical question and compared the direction of treatment effects, effect sizes, and confidence intervals. RESULTS: The main analysis included 19 MSM-studies (1,039,570 patients) and 141 RCTs (120,669 patients). MSM-studies indicated effect estimates in the opposite direction from RCTs for eight clinical questions (42%), and their 95% CI (confidence interval) did not include the RCT estimate in nine clinical questions (47%). The effect estimates deviated 1.58-fold between the study designs (median absolute deviation OR [odds ratio] 1.58; IQR [interquartile range] 1.37 to 2.16). Overall, we found no systematic disagreement regarding benefit or harm but confidence intervals were wide (summary ratio of odds ratios [sROR] 1.04; 95% CI 0.88 to 1.23). The subset of MSM-studies focusing on healthcare decision-making tended to overestimate experimental treatment benefits (sROR 1.44; 95% CI 0.99 to 2.09). CONCLUSION: Nonrandomized studies using causal modeling with MSM may give different answers than RCTs. Caution is still required when nonrandomized "real world" evidence is used for healthcare decisions.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Ewald H, Ioannidis JPA, Ladanie A, et al. Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study. J Clin Epidemiol. 2019. PMID: 31704350. doi:10.1016/j.jclinepi.2019.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。